AstraZeneca said on January 13 that preliminary data from a trial showed that the company’s COVID-19 shot Vaxzevria generated an increase in antibodies against the Omicron and other variants when given as a third booster dose.
Ovid Therapeutics has partnered with AstraZeneca for exclusive access to a library of early-stage small molecules that target the KCC2 transporter, including OV350 — the lead candidate.
AstraZeneca and Ionis Pharmaceuticals closed out 2021 with the finalization of their collaboration on the development and potential commercialization of eplontersen, an experimental treatment for transthyretin amyloidosis (ATTR).
A three-dose course of AstraZeneca’s Covid-19 vaccine is effective against the rapidly spreading Omicron coronavirus variant, the pharmaceutical company said on December 23, citing data from an Oxford University lab study.
The U.S. Food and Drug Administration approved AstraZeneca and Amgen’s drug Tezspire to treat severe asthma for those aged 12 years and older, the companies said on December 17.
AstraZeneca reported that the company’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody cocktail, was able to neutralize the Omicron variant to SARS-CoV-2.
Samsung Biologics Co. Ltd. said on December 13 the company would continue its partnership with AstraZeneca Plc on manufacturing biopharmaceuticals.
The U.S. Food and Drug Administration on December 8 authorized the use of AstraZeneca’s antibody cocktail to prevent Covid-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.
Carlsbad, Calif.-based Ionis Pharmaceuticals inked a collaboration deal with AstraZeneca to develop and commercialize eplontersen for transthyretin amyloidosis (ATTR).
A major British study into mixing Covid-19 vaccines found that people had a better immune response when they received a first dose of AstraZeneca or Pfizer-BioNTech shots followed by Moderna nine weeks later, according to the results on December 6.
